Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

Healthcare professionals who identify patients who develop heart failure symptoms while taking alogliptin or saxagliptin should consider discontinuing these medications and seek other medications for glucose control.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to medication use to FDA’s MedWatch Adverse Event Reporting Program.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Pfizer Inc. News release: Pfizer announces positive top-line results from the first phase 3 trial of investigational tofacitinib in adults with psoriatic arthritis. 2016 Apr 5.
U.S. Food and Drug Administration. Safety alert: Diabetes medications containing aaxagliptin and slogliptin: drug safety communication—risk of heart failure. 2016 Apr 5.

Severe and disabling joint pain has been connected to the use of dipeptidyl peptidase-4 inhibitors and combination therapies for diabetes, prompting a new FDA warning…

Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

FDA Issues Warning for Joint Pain from Diabetes Drugs

Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Related Articles